Achilles Therapeutics to Present at Upcoming Scientific Congresses
10/01/2021 - 08:00 AM
LONDON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present an oral presentation at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress being held in a virtual format from October 19-22, 2021, and two posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in a hybrid format from November 10-14, 2021 online and in person in Washington, DC.
Details of the presentations are as follows:
2021 European Society for Gene and Cell Therapy (ESGCT) Congress Abstract Title: Multicentre, prospective research protocol for development of a clonal neoantigen-reactive T cell therapy pipeline across multiple tumour typesPresentation Number: OR54Session: 6c ManufacturingSession Time: Friday, October 22, 2021: 9:00am–11:00am CEST (3:00am–5:00am ET)Presenter: Michael Grant, MB, BCh, BAO, BSc, PGCert, FHEA, Associate Medical Director, Achilles Therapeutics Full ESGCT abstract details will be available October 19, 2021. Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Abstract Title : Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulationPoster Number: 543Poster Presenter: Samra Turajlic, MD, MBBS, MRCP, PhD, THETIS Chief Investigator, Royal Marsden, London, UKAbstract Title : The Achilles VELOS™ Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapiesPoster Number: 193Poster Presenter: Joseph Robinson, PhD, Senior Scientist, Process Development, Achilles Therapeutics Full SITC abstract details will be available on November 9, 2021 and posters will be available on November 12, 2021. About Achilles Therapeutics Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with unresectable locally advanced and metastatic non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Forward-Looking Statements This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Further information:
Lee M. Stern – VP, IR & External Communications +1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic Communications Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner +44 (0) 203 709 5000achillestx@consilium-comms.com
Achilles Therapeutics Plc
ACHL Rankings
#4769 Ranked by Stock Gains
ACHL Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Country
United Kingdom
City
245 Hammersmith Road
About ACHL
achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.